Total: $187.08M

Company (Symbol)# (M)

Type Of Financing

Number Of Shares, Units Or Warrants

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


AspenBio Inc.
(OTC BB:APNB)

Private
placement
of units

N/A

$1.25

The units were sold at $17,500 each and each consists of 20,000 unregistered shares and 20,000 warrants exercisable for three years at $1.50 per share (7/21)

Calypte
Biomedical
Corp.
(OTC BB:CYPT)

Private
placement of
stock and
warrants

3.7S and
2.6W

$1.5

The shares were sold for $0.40 each and the five-year warrants are exercisable at $0.50 per share, the same terms as the first part of the financing in June that brought in $9.3M (7/13)

Cellegy
Pharmaceuticals
Inc.
(CLGY)

Private
placement of
stock and
warrants

3.02S and
0.604W

$10.3

Shares in the private placement, primarily with institutional investors, were sold at $3.42 each; the warrants are exercisable at $4.62 per share (7/27)

ConjuChem
Inc.
(Canada;
TSE:CJC)

Private
placement of
convertible
notes and
warrants

N/A

C$25
(US$18.9)

The 7.07% notes were sold to Baker Brothers Investments and can be converted into common stock at C$5 per share; the deal also includes 0.35 warrants per underlying common share exercisable at C$6.25 per share (7/20)

Corautus
Genetics Inc.
(AMEX:CAQ)

Convertible
debt facility

N/A

$5

Corautus closed on a $5M loan from Boston Scientific Corp. under a July 2003 agreement; the loan could increase to up to $15M under the milestone-driven deal (7/26)

Corautus
Genetics Inc.
(AMEX:CAQ)

Private
placement of
stock and
warrants

0.943S and
0.236W

$4.93

Shares in the first tranche of a financing were sold at $5.22 each; the second tranche would include the same number of shares on the same terms; each tranche includes 235,869 warrants exercisable at a 20% premium at the time of the deal (7/7)

Evotec OAI
AG
(Germany;
FSE:EVT)

Private
placement of
stock

2.5S

€7.5
(US$9.2)

The shares were sold at €3 each; Sal. Oppenheim was global coordinator for the financing (7/14)

Generex
Biotechnology
Corp.
(Canada;
GNBT)

Private
placement of
stock and
warrants

2.46S and
1.97W

$3

The warrants in the deal are exercisable at $1.68 per share; the four participating investors have an option to purchase the same number of shares and warrants on the same terms (7/13)

GlycoGenesys
Inc.
(GLGS)

Private
placement of
stock and warrants

10S and
8W

$5

Institutions purchased the shares at $0.50 each and the warrants are exercisable at $1 per share (7/12)

Idenix
Pharmaceuticals
Inc.
(IDIX)

Private
placement of
stock

5.4S

$75.6

The shares were sold to Novartis Pharma AG in conjunction with Idenix's IPO; the stock was sold at the IPO price of $14 per share; Novartis retained its 57% stake in Idenix through the purchase (7/21)

Miraculins
Inc.
(Canada;
VSE:MOM)

Private
placement of
units

1U

C$0.4
(US$0.3)

Each unit consists of one share and one-half of a warrant; each full warrant is convertible for six months into a common share at C$1.55; McFarlane Gordon Inc. and Bieber Securities Inc. were agents for the offering, and received 36,000 warrants exercisable at C$1.25 as part of the deal (7/27)

MultiCell
Technologies
Inc.
(OTC BB:
MUCL)

Private sale
of convertible
stock and
warrants

ND

$2

Ascendiant Securities LLC was placement agent in the deal, which entailed the sale of convertible preferred stock and warrants (7/13)

Norwood
Abbey Ltd.
(Australia;
ASX:NAL)

Options
exercise

ND

$10.1

Norwood Abbey raised $10.1M from the exercise of options that expired June 30 (7/1)

Novavax Inc.
(NVAX)

Private
placement of
of convertible
notes and stock

N/A and
0.952S

$40

In conjunction with its reacquisition of Estrasorb from King Pharmaceuticals Inc., Novavax sold 4.75% senior convertible notes to institutional investors along with 952,381 common shares at $5.25 per share; the notes are convertible into stock at $6.15 per share (7/19)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

Currencies conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.